A new oral anticoagulant: the 50-year challenge.
AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. david.gustafsson@astrazeneca.com
David
D
Gustafsson
Ruth
R
Bylund
Thomas
T
Antonsson
Ingemar
I
Nilsson
Jan-Erik
JE
Nyström
Ulf
U
Eriksson
Ulf
U
Bredberg
Ann-Catrine
AC
Teger-Nilsson
D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D001384:Azetidines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D001596:Benzylamines; D001682:Biological Availability; D001777:Blood Coagulation / Q000502:physiology*; D006801:Humans; D007408:Intestinal Absorption; D011355:Prodrugs / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D011355:Prodrugs; C426686:ximelagatran